Ablation of the complement C3a anaphylatoxin receptor causes enhanced killing of Pseudomonas aeruginosa in a mouse model of pneumonia

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 291, Issue 2, 2006, Pages

  Mueller Ortiz, Stacey L ^a   Hollmann, Travis J ^a   Haviland, David L ^a   Wetsel, Rick A ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Antibody; Bacteria; Infection; Inflammation; Pulmonary

Indexed keywords

ANAPHYLATOXIN; BACTERIUM ANTIBODY; CHEMOKINE; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3A RECEPTOR; CYTOKINE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIAL INFECTION; BACTERIUM ADHERENCE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNIZATION; INFLAMMATION; LOBAR PNEUMONIA; LUNG INFECTION; LUNG INFILTRATE; MOUSE; NONHUMAN; PHAGOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PSEUDOMONAS AERUGINOSA;

ANIMALS; ANTIBODIES; BRONCHOALVEOLAR LAVAGE FLUID; CHEMOKINES; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; LUNG; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PNEUMONIA; PSEUDOMONAS AERUGINOSA; REACTIVE OXYGEN SPECIES; RECEPTORS, COMPLEMENT;

EID: 33746626434     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00358.2005     Document Type: Article

References (63)

1. Ames RS, Li Y, Sarau HM, Nuthulaganti P, Foley JJ, Ellis C, Zeng Z, Su K, Jurewicz AJ, Hertzberg RP, Bergsma DJ, and Kumar C. Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J Biol Chem 271: 20231-20234, 1996.
2. Bautsch W, Hoymann HG, Zhang Q, Meier-Wiedenbach I, Raschke U, Ames RS, Sohns B, Flemme N, Meyer zu Vilsendorf A, Grove M, Klos A, and Kohl J. Cutting edge: guinea pigs with a natural C3a-receptor defect exhibit decreased bronchoconstriction in allergic airway disease: evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma. J Immunol 165: 5401-5405, 2000.
3. Bottazzi B, Walter S, Govoni D, Colotta F, and Mantovani A. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J Immunol 148: 1280-1285, 1992.
4. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, and David JR. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 189: 341-346, 1999.
5. Braun MC, Reins RY, Li TB, Hollmann TJ, Dutta R, Wetsel RA, Teng BB, and Ke B. Renal expression of the C3a receptor and functional responses of primary human proximal tubular epithelial cells. J Immunol 173: 4190-4196, 2004.
6. Crass T, Raffetseder U, Martin U, Grove M, Klos A, Kohl J, and Bautsch W. Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells. Eur J Immunol 26: 1944-1950, 1996.
7. Daffern PJ, Pfeifer PH, Ember JA, and Hugli TE. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med 181: 2119-2127, 1995.
8. Davoust N, Jones J, Stahel PF, Ames RS, and Barnum SR. Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells. Glia 26: 201-211, 1999.
9. Digiandomenico A, Rao J, and Goldberg JB. Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model. Infect Immun 72: 7012-7021, 2004.
10. Driscoll KE. Macrophage inflammatory proteins: biology and role in pulmonary inflammation. Exp Lung Res 20: 473-490, 1994.
11. Drouin SM, Kildsgaard J, Haviland J, Zabner J, Jia HP, McCray PB Jr, Tack BF, and Wetsel RA. Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J Immunol 166: 2025-2032, 2001.
12. Drouin SM, Corry DB, Hollman TJ, Kildsgaard J, and Wetsel RA. Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J Immunol 169: 5926-5933, 2002.
13. Drouin SM, Corry DB, and Wetsel RA. Increased inflammation and airway hyperresponsiveness in C5-deficient mice reveal opposite roles for C3a and C5a in mediating Th2 effector functions in experimental asthma (Abstract). Mol Immunol 41: A51, 2004.
14. Dunkley ML, Rajyaguru S, McCue A, Cripps AW, and Kyd JM. Pseudomonas aeruginosa-specific IgG1 and IgG2 subclasses in enhancement of pulmonary clearance following passive immunisation in the rat. FEMS Immunol Med Microbiol 39: 37-44, 2003.
15. Edens HA and Parkos CA. Neutrophil transendothelial migration and alteration in vascular permeability: focus on neutrophil-derived azurocidin. Curr Opin Hematol 10: 25-30, 2003.
16. Ehrengruber MU, Geiser T, and Deranleau DA. Activation of human neutrophils by C3a and C5a. Comparison of the effects on shape changes, chemotaxis, secretion, and respiratory burst. FEBS Lett 346: 181-184, 1994.
17. Elsner J, Oppermann M, Czech W, Dobos G, Schopf E, Norgauer J, and Kapp A. C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol 24: 518-522, 1994.
18. Elsner J, Oppermann M, Czech W, and Kapp A. C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins. Blood 83: 3324-3331, 1994.
19. Fischer WH and Hugli TE. Regulation of B cell functions by C3a and C3a(desArg): suppression of TNF-α, IL-6, and the polyclonal immune response. J Immunol 159: 4279-4286, 1997.
20. Fischer WH, Jagels MA, and Hugli TE. Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(desArg). J Immunol 162: 453-459, 1999.
21. Frank DW, Vallis A, Wiener-Kronish JP, Roy-Burman A, Spack EG, Mullaney BP, Megdoud M, Marks JD, Fritz R, and Sawa T. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 186: 64-73, 2002.
22. Fukuoka Y and Hugli TE. Demonstration of a specific C3a receptor on guinea pig platelets. J Immunol 140: 3496-3501, 1988.
23. Gasque P, Singhrao SK, Neal JW, Wang P, Sayah S, Fontaine M, and Morgan BP. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J Immunol 160: 3543-3554, 1998.
24. Gu L, Rutledge B, Fiorillo J, Ernst C, Grewal I, Flavell R, Gladue R, and Rollins B. In vivo properties of monocyte chemoattractant protein-1. J Leukoc Biol 62: 577-580, 1997.
25. Haeffner-Cavaillon N, Cavaillon JM, Laude M, and Kazatchkine MD. C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes. J Immunol 139: 794-799, 1987.
26. Hamer PW, McGeachie JM, Davies MJ, and Grounds MD. Evans blue dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability. J Anat 200: 69-79, 2002.
27. Hartmann K, Henz BM, Kruger-Krasagakes S, Kohl J, Burger R, Guhl S, Haase I, Lippert U, and Zuberbier T. C3a and C5a stimulate chemotaxis of human mast cells. Blood 89: 2863-2870, 1997.
28. Heale JP, Pollard AJ, Stokes RW, Simpson D, Tsang A, Massing B, and Speert DP. Two distinct receptors mediate nonopsonic phagocytosis of different strains of Pseudomonas aeruginosa. J Infect Dis 183: 1214-1220, 2001.
29. Hemachandra S, Kamboj K, Copfer J, Pier G, Green LL, and Schreiber JR. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis. Infect Immun 69: 2223-2229, 2001.
30. Hogan B, Costantini F, and Lacy E. Manipulating the Mouse Embryo. New York: Cold Spring Harbor, 1986.
31. Hopken UE, Lu B, Gerard NP, and Gerard C. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 383: 86-89, 1996.
32. Humbles AA, Lu B, Nilsson CA, Lilly C, Israel E, Fujiwara Y, Gerard NP, and Gerard C. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 406: 998-1001, 2000.
33. Janeway CA, Travers P, Walport M, and Shlomchik M. Innate immunity. In: Immunobiology (5th ed.). New York: Garland, 2001.
34. Kildsgaard J, Hollmann TJ, Matthews KW, Bian K, Murad F, and Wetsel RA. Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J Immunol 165: 5406-5409, 2000.
35. + dendritic cells derived from human skin. Immunology 103: 210-217, 2001.
36. Kohl J, Hawlisch H, Best J, Herman N, Sproles A, Zwirner J, and Wills-Karp M. A critical role of C5a in the sensitization and the effector phase of experimental allergic asthma (Abstract). Mol Immunol 41: A125, 2004.
37. Liu PV. The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis. III. Identity of the lethal toxins produced in vitro and in vivo. J Infect Dis 116: 481-489, 1966.
38. Lyczak JB, Cannon CL, and Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 15: 194-222, 2002.
39. Monsinjon T, Gasque P, Ischenko A, and Fontaine M. C3a binds to the seven transmembrane anaphylatoxin receptor expressed by epithelial cells and triggers the production of IL-8. FEBS Lett 487: 339-346, 2001.
40. Monsinjon T, Gasque P, Chan P, Ischenko A, Brady JJ, and Fontaine MC. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 17: 1003-1014, 2003.
41. Morgan EL, Weigle WO, and Hugli TE. Anaphylatoxin-mediated regulation of the immune response. I. C3a-mediated suppression of human and murine humoral immune responses. J Exp Med 155: 1412-1426, 1982.
42. + suppressor T cells. Clin Immunol Immunopathol 37: 114-123, 1985.
43. + suppressor T cell. J Immunol 134: 51-57, 1985.
44. Murakami Y, Imamichi T, and Nagasawa S. Characterization of C3a anaphylatoxin receptor on guinea-pig macrophages. Immunology 79: 633-638, 1993.
45. Nilsson G, Johnell M, Hammer CH, Tiffany HL, Nilsson K, Metcalfe DD, Siegbahn A, and Murphy PM. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol 157: 1693-1698, 1996.
46. Pier GB, Boyer D, Preston M, Coleman FT, Llosa N, Mueschenborn-Koglin S, Theilacker C, Goldenberg H, Uchin J, Priebe GP, Grout M, Posner M, and Cavacini L. Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J Immunol 173: 5671-5678, 2004.
47. Price BM, Barten Legutki J, Galloway DR, von Specht BU, Gilleland LB, Gilleland HE, and Staczek J. Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa. FEMS Immunol Med Microbiol 33: 89-99, 2002.
48. Priebe GP, Meluleni GJ, Coleman FT, Goldberg JB, and Pier GB. Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant. Infect Immun 71: 1453-1461, 2003.
49. Roglic A, Prossnitz ER, Cavanagh SL, Pan Z, Zou A, and Ye RD. cDNA cloning of a novel G protein-coupled receptor with a large extracellular loop structure. Biochim Biophys Acta 1305: 39-43, 1996.
50. Schultz MJ, Rijneveld AW, Speelman P, van Deventer SJ, and van der Poll T. Endogenous interferon-gamma impairs bacterial clearance from lungs during Pseudomonas aeruginosa pneumonia. Eur Cytokine Netw 12: 39-44, 2001.
51. Schultz MJ, Rijneveld AW, Florquin S, Edwards CK, Dinarello CA, and van der Poll T. Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol 282: L285-L290, 2002.
52. Schultz MJ, Knapp S, Florquin S, Pater J, Takeda K, Akira S, and van der Poll T. Interleukin-18 impairs the pulmonary host response to Pseudomonas aeruginosa. Infect Immun 71: 1630-1634, 2003.
53. Shime N, Sawa T, Fujimoto J, Faure K, Allmond LR, Karaca T, Swanson BL, Spack EG, and Wiener-Kronish JP. Therapeutic administration of anti-PcrV F(ab′)(2) in sepsis associated with Pseudomonas aeruginosa. J Immunol 167: 5880-5886, 2001.
54. Sordelli DO, Cerquetti MC, Morris Hooke A, and Bellanti JA. Effect of chemotactins released by Staphylococcus aureus and Pseudomonas aeruginosa on the murine respiratory tract. Infect Immun 49: 265-269, 1985.
55. Takabayashi T, Vannier E, Clark BD, Margolis NH, Dinarello CA, Burke JF, and Gelfand JA. A new biologic role for C3a and C3a desArg: regulation of TNF-α and IL-1β synthesis. J Immunol 156: 3455-3460, 1996.
56. Takabayashi T, Vannier E, Burke JF, Tompkins RG, Gelfand JA, and Clark BD. Both C3a and C3a(desArg) regulate interleukin-6 synthesis in human peripheral blood mononuclear cells. J Infect Dis 177: 1622-1628, 1998.
57. Van Damme J, Wuyts A, Froyen G, Van Coillie E, Struyf S, Billiau A, Proost P, Wang JM, and Opdenakker G. Granulocyte chemotactic protein-2 and related CXC chemokines: from gene regulation to receptor usage. J Leukoc Biol 62: 563-569, 1997.
58. Vogt W. Anaphylatoxins: possible roles in disease. Complement 3: 177-188, 1986.
59. Vowells SJ, Sekhsaria S, Malech HL, Shalit M, and Fleisher TA. Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes. J Immunol Methods 178: 89-97, 1995.
60. Ward PA, Lepow IH, and Newman LJ. Bacterial factors chemotactic for polymorphonuclear leukocytes. Am J Pathol 52: 725-736, 1968.
61. Werfel T, Kirchhoff K, Wittmann M, Begemann G, Kapp A, Heidenreich F, Gotze O, and Zwirner J. Activated human T lymphocytes express a functional C3a receptor. J Immunol 165: 6599-6605, 2000.
62. Wetsel RA, Kildsgaard J, and Haviland DL. Complement anaphylatoxins (C3a, C4a, C5a) and their receptors (C3aR, C5aR/CD88) as therapeutic targets in inflammation. In: Contemporary Immunology: Therapeutic Interventions in the Complement System, edited by Lambris JD and Holers VM. Totowa, NJ: Humana, 2000, p. 113.
63. Zwirner J, Gotze O, Begemann G, Kapp A, Kirchhoff K, and Werfel T. Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies. Immunology 97: 166-172, 1999.